(Q38460074)

3 September 2017

Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas (English)

1 reference

3 September 2017

Maitra A

1

1 reference

3 September 2017

Wanzer D

series ordinal

2

1 reference

3 September 2017

Weinberg AG

series ordinal

3

1 reference

3 September 2017

Ashfaq R

series ordinal

4

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

3 September 2017

1 reference

3 September 2017

92

1 reference

3 September 2017

3

1 reference

3 September 2017

677-683

1 reference

Tumor size and prognosis in aggressively treated osteosarcoma

3 September 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Prognostic factors in osteosarcoma: a critical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Prognostic variables in osteosarcoma: a multi-institutional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Growth factor receptor and related oncogene determination in mesenchymal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Altered G1 phase regulation in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Expression of HER2/erbB-2 correlates with survival in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Osteosarcoma: pathology and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C677%3A%3AAID-CNCR1370%3E3.0.CO%3B2-V

10.1002/1097-0142(20010801)92:3<677::AID-CNCR1370>3.0.CO;2-V

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference